We encourage each patient to prepare and ask questions, and raise any concerns they may have
two months in, you may notice you need less concealer on dark spots, or your tan from last summer has faded more than usual
J., Chambers, J
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
The incision-free procedure is fast and easy, and requires no downtime from normal activities
Its been another relatively quiet year on the mergers and acquisitions front, with only one eight-figure deal signed Novo Holdings $16.5 billion bid for struggling contract manufacturer Catalent, including an $11 billion deal with daughter firm Novo Nordisk to pass on three fill-and-finish facilities in the US, Belgium and Italy that would help solve some of Novos capacity headache for GLP-1 medicines